Skip to main content
HUALAN GROUP CO.,LTD. logo

HUALAN GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 301027 ISIN · CNE100004MH7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 662 across all filing types
Latest filing 2021-12-10 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301027

About HUALAN GROUP CO.,LTD.

https://www.gxhl.com

Hualan Group Co., Ltd. specializes in the research, development, and manufacturing of primary pharmaceutical packaging materials. The company's core product portfolio includes high-quality butyl rubber stoppers, aluminum-plastic combination caps, and plastic components designed for injectable medications and infusion sets. These products are engineered to ensure drug stability and compatibility, meeting international quality standards such as GMP. Serving a global clientele of pharmaceutical manufacturers, the group focuses on advanced material science and precision manufacturing to provide secure sealing solutions for vaccines, antibiotics, and blood products. By integrating R&D with large-scale production capabilities, the company maintains a significant role in the pharmaceutical supply chain, emphasizing safety and reliability in drug delivery systems.

Recent filings

Filing Released Lang Actions
第三届董事会第二十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board of directors meeting of 华蓝集团股份公司 held on December 10, 2021. It details the approval of proposals related to adjustments in the use of raised funds, replacement of pre-invested funds with raised funds, and use of raised funds to supplement working capital. The document includes voting results and references to related announcements and verification reports but does not contain financial statements or detailed financial data itself. The content focuses on board decisions and approvals rather than full management reports or financial disclosures. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document length is short (1646 characters), and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2021-12-10 Chinese
关于华蓝集团股份公司以自筹资金预先投入募投项目的鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "鉴证报告" (verification report) regarding the use of self-raised funds to pre-invest in projects intended to be funded by raised capital. It includes a verification opinion by a registered accountant and detailed explanations about the use of funds, investment projects, and compliance with Shenzhen Stock Exchange guidelines. The document references regulatory approvals and accounting verification reports. It is a standalone audit-related verification report focusing on the use of funds and compliance, not a full annual or interim financial report. The length is under 5,000 characters but contains substantive verification content, not merely an announcement. Therefore, it fits best under Audit Report / Information (AR). FY 2021
2021-12-10 Chinese
太平洋证券关于华蓝集团调整募集资金投资项目拟投入募集资金金额的核查意见
Audit Report / Information Classification · 95% confidence The document is a formal verification opinion from a sponsoring securities company regarding the adjustment of the amount of raised funds to be invested in specific projects by a company (华蓝集团股份公司). It references regulatory approvals, fundraising details, board and supervisory committee approvals, and compliance with relevant laws and regulations. The document is focused on the verification and opinion on the adjustment of investment amounts from the raised funds, not the full annual or interim financial report. It is a specialized audit or verification report related to fundraising and investment project adjustments, which fits the category of an Audit Report / Information (AR). The document length is 2428 characters, which is relatively short but contains substantive content and formal opinions, not just an announcement or certification. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). FY 2021
2021-12-10 Chinese
独立董事关于第三届第二十五次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the 25th meeting of the third board of directors of 华蓝集团股份公司. It focuses on the approval and compliance of adjustments related to the use of raised funds, including investment project amounts, replacement of pre-invested funds, and supplementing working capital. The document references relevant laws, regulations, and stock exchange rules regarding the management and use of raised funds. It is a formal opinion letter from independent directors rather than a full financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data but rather a governance-related opinion on fundraising and fund usage matters. Therefore, it fits best under the category of Regulatory Filings (RNS), as it is a compliance-related announcement that does not fit other specific categories like Capital/Financing Update (CAP) or Management Reports (MDA). The document length is short (1146 characters), and it is not a report publication announcement or certification letter but an independent opinion on board matters related to fundraising usage.
2021-12-10 Chinese
太平洋证券关于华蓝集团使用募集资金置换已预先投入募投项目及已支付发行费用自筹资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsor (Pacific Securities Co., Ltd.) regarding the use of raised funds by Hualan Group Co., Ltd. to replace self-raised funds previously invested in projects and issuance expenses. It references regulatory approvals, fundraising details, investment projects, board and supervisory committee approvals, and an auditor's special verification report. The document is a formal verification and opinion letter related to the fundraising and use of proceeds, not the fundraising report itself or a financial statement. It is a regulatory compliance and verification document related to capital use and fundraising, typical of a Regulatory Filings (RNS) type. The document length is under 5,000 characters and it is not a full financial report or earnings release, nor a proxy or AGM material. Therefore, it fits best under Regulatory Filings (RNS).
2021-12-10 Chinese
关于以募集资金置换预先投入募投项目及已支付发行费用自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 华蓝集团股份公司 regarding the use of raised funds to replace previously invested self-raised funds in investment projects and issuance expenses. It details the approval by the board and supervisory committee, the amount of funds raised, the projects involved, and includes opinions from independent directors, the supervisory board, the sponsor institution, and an accounting firm. The document is a formal disclosure about the company's capital usage and fund replacement, not a full financial report or earnings release. It is specifically about fundraising and capital allocation updates, which fits the Capital/Financing Update (CAP) category. The document length is 4268 characters, which is substantial but not a full annual or interim report. It is not a report publication announcement since it contains detailed information rather than just a notice of report availability.
2021-12-10 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.